Recombinant Human Interferon Beta 1B

Recombinant Human Interferon Beta 1B, also known as rh IFN-beta 1b,
is used to slow the progression of relapsing multiple sclerosis (MS) and reduce the frequency of clinical symptoms associated with this autoimmune disease. Its immune-modulating properties can be used also in viral and oncological diseases.
It is a single, non-glycosylated mutein (variant form) of the human Interferon beta-1b polypeptide chain.

Transfer of the end-to-end technology available in GMP-like environment.

Recombinant human Interferon Beta 1b (rhIFN beta 1b) is produced in E.coli using
an expression vector driven by the T7 promoter.
Production: the yield is around 40 mg/L (not purified) of rhIFN beta 1b.
rhIFN beta 1b is purified from inclusion bodies by solubilization and cation exchange chromatography. Final yield of the process is around 20%. The purity of the product is at least 95% by RP-HPLC analysis.

Antiviral and Immunomodulatory Activities: IFN-β1b is secreted by cells in response to viral infections. It has antiviral, anti-proliferative, and multifunctional immunomodulatory activities.
Multiple Sclerosis Treatment: IFN-β1b is a first-line treatment for multiple sclerosis.